Sfoglia per Autore
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
2024 Carbone, M; Neuberger, J; Rowe, I; Polak, W; Forsberg, A; Fondevila, C; Mantovani, L; Nardi, A; Colli, A; Rockell, K; Schick, L; Cristoferi, L; Oniscu, G; Strazzabosco, M; Cillo, U
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score
2024 Gerussi, A; Cappadona, C; Bernasconi, D; Cristoferi, L; Valsecchi, M; Carbone, M; Invernizzi, P; Asselta, R
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
2024 Corpechot, C; Lemoinne, S; Soret, P; Hansen, B; Hirschfield, G; Gulamhusein, A; Montano-Loza, A; Lytvyak, E; Pares, A; Olivas, I; Eaton, J; Osman, K; Schramm, C; Sebode, M; Lohse, A; Dalekos, G; Gatselis, N; Nevens, F; Cazzagon, N; Zago, A; Russo, F; Floreani, A; Abbas, N; Trivedi, P; Thorburn, D; Saffioti, F; Barkai, L; Roccarina, D; Calvaruso, V; Fichera, A; Delamarre, A; Sobenko, N; Villamil, A; Medina-Morales, E; Bonder, A; Patwardhan, V; Rigamonti, C; Carbone, M; Invernizzi, P; Cristoferi, L; Van Der Meer, A; De Veer, R; Zigmond, E; Yehezkel, E; Kremer, A; Deibel, A; Bruns, T; Grosse, K; Wetten, A; Dyson, J; Jones, D; Dumortier, J; Pageaux, G; De Ledinghen, V; Chazouilleres, O; Carrat, F
Patient-reported quality of care in primary sclerosing cholangitis
2023 Walmsley, M; Tornai, D; Cazzagon, N; Leburgue, A; Mrzljak, A; Lenzen, H; Carbone, M; Madaleno, J; Lleo, A; Junge, N; Schramm, C; Bergquist, A
The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis
2023 Christine Halma, J; Cristoferi, L; Carbone, M
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement
2023 Carbone, M; Della Penna, A; Mazzarelli, C; De Martin, E; Villard, C; Bergquist, A; Line, P; Neuberger, J; Al-Shakhshir, S; Trivedi, P; Baumann, U; Cristoferi, L; Hov, J; Fischler, B; Hadzic, N; Debray, D; D'Antiga, L; Selzner, N; Belli, L; Nadalin, S
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival
2023 Murilloperez, C; Ioannou, S; Hassanally, I; Trivedi, P; Corpechot, C; van der Meer, A; Lammers, W; Battezzati, P; Lindor, K; Nevens, F; Kowdley, K; Bruns, T; Cazzagon, N; Floreani, A; Mason, A; Gulamhusein, A; Ponsioen, C; Carbone, M; Lleo, A; Mayo, M; Dalekos, G; Gatselis, N; Thorburn, D; Verhelst, X; Pares, A; Londono, M; Janssen, H; Invernizzi, P; Vuppalanchi, R; Hirschfield, G; Hansen, B; Levy, C
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe
2023 Murillo Perez, C; Gerussi, A; Trivedi, P; Corpechot, C; Van Der Meer, A; Maria Battezzati, P; Lindor, K; Nevens, F; Kowdley, K; Bruns, T; Cazzagon, N; Floreani, A; Tanaka, A; Ma, X; Mason, A; Gulamhusein, A; Ponsioen, C; Carbone, M; Lleo, A; Mayo, M; Dalekos, G; Gatselis, N; Thorburn, D; Verhelst, X; Pares, A; Janssen, H; Hirschfield, G; Hansen, B; Invernizzi, P; Lammers, W
Autoimmune liver diseases
2023 Scaravaglio, M; Carbone, M; Invernizzi, P
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States
2023 Ciardullo, S; Carbone, M; Invernizzi, P; Perseghin, G
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)]
2023 Cordell, H; Fryett, J; Ueno, K; Darlay, R; Aiba, Y; Hitomi, Y; Kawashima, M; Nishida, N; Khor, S; Gervais, O; Kawai, Y; Nagasaki, M; Tokunaga, K; Tang, R; Shi, Y; Li, Z; Juran, B; Atkinson, E; Gerussi, A; Carbone, M; Asselta, R; Cheung, A; de Andrade, M; Baras, A; Horowitz, J; Ferreira, M; Sun, D; Jones, D; Flack, S; Spicer, A; Mulcahy, V; Byan, J; Han, Y; Sandford, R; Lazaridis, K; Amos, C; Hirschfield, G; Seldin, M; Invernizzi, P; Siminovitch, K; Ma, X; Nakamura, M; Mells, G
Artificial Intelligence and liver: Opportunities and barriers
2023 Balsano, C; Burra, P; Duvoux, C; Alisi, A; Piscaglia, F; Gerussi, A; Brunetto, M; Bonino, F; Montalti, R; Campanile, S; Persico, M; Alvaro, D; Santini, S; Invernizzi, P; Carbone, M; Masarone, M; Eccher, A; Siciliano, B; Vento, M; Ficuciello, F; Cabitza, F; Penasa, S; Donatelli, P
Open challenges in the management of autoimmune hepatitis
2023 Gerussi, A; Halliday, N; Carbone, M; Invernizzi, P; Thorburn, D
Risk stratification in primary sclerosing cholangitis
2023 Mulinacci, G; Cristoferi, L; Palermo, A; Lucà, M; Gerussi, A; Invernizzi, P; Carbone, M
Authors' reply to Zou et al
2023 Ciardullo, S; Carbone, M; Invernizzi, P; Perseghin, G
Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis
2023 Gazda, J; Drazilova, S; Gazda, M; Janicko, M; Koky, T; Macej, M; Carbone, M; Jarcuska, P
Intensive care management of acute-on-chronic liver failure
2023 Perricone, G; Artzner, T; De Martin, E; Jalan, R; Wendon, J; Carbone, M
Endocrinology and Metabolic Diseases (Including Diabetes)
2023 Cristoferi, L; Ciardullo, S; Invernizzi, P; Perseghin, G; Carbone, M
Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial
2023 Invernizzi, P; Carbone, M; Jones, D; Levy, C; Little, N; Wiesel, P; Nevens, F
Prognostic models and autoimmune liver diseases
2023 D'Amato, D; Carbone, M
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile